Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Technology Transfer from the Weizmann Institute of Science

f r o m o u r p i p e l i n e t o y o u r b o t t o m l i n e

Amir Naiberg, CEO

TTO Circle

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

The Weizmann Institute of Science Discovering Basic Science

Yeda R&D Co. Ltd. Bridging Research & Development

Past & Present Success Stories Anatomies of Success

Lessons learned

From Our Pipeline to Your Bottom Line

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

First Biotech Invention

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

And the Reward

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Imagine life without:

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Healing, Fueling, Feeding

Cherry Tomato Hybrids Sandisk Chip

Polymerico Fiber Optics

Mobileye Motorola Barcode Reader

Wheat Variants NDS Smart Card

HelioFocus

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Weizmann Institute of Science Curiosity Driven Research

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

What will be the next scientific revolution?

Who will make the next scientific revolution?

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

The next scientific revolution will be • driven by scientists who

have a multidisciplinary view of science

• the opportunity to take risks

• the infrastructure to work • the freedom to think

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

The Weizmann Institute of Science Focused on Research

400 administrative staff

10%

34%

40%

16%

260 professors Heading research groups

850 scientists Ph.D.’s, engineers & technicians

1,000 students M.Sc. and Ph.D. only

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

ERC Ranking

The highest success rate in the EU - close to 60% compared with 9% EU average

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Enhancing medical treatment efficacy using the most advanced research tools

The Israel National Center for Personalized Medicine

BENCH TO BEDSIDE

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

The Need to Re-think Innovation

Sources: InnoThink Center For Research In Biomedical Innovation; Thomson Reuters Fundamentals via FactSet Research Systems The Truly Staggering Cost Of Inventing New Drugs, Matthew Herper (Forbes, 10.2.2012)

Number of Drugs Approved

R&D Spending Per Drug ($Mil)

Total R&D Spending 1997-2011 ($Mil)

Company

5 11,790.93 58,955 AstraZeneca

10 8,170.81 81,708 GlaxoSmithKline

8 7,909.26 63,274 Sanofi

11 7,803.77 85,841 Roche Holding AG

14 7,727.03 108,178 Pfizer Inc.

15 5,885.65 88,285 Johnson & Johnson

11 4,577.04 50,347 Eli Lilly & Co.

8 4,496.21 35,970 Abbott Laboratories

16 4,209.99 67,360 Merck & Co Inc

11 4,152.26 45,675 Bristol-Myers Squibb Co.

21 3,983.13 83,646 Novartis AG

9 3,692.14 33,229 Amgen Inc.

139 5,773 802,468 Total

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

BIOTECHNOLOGY

Name of Drug/Company Indication 2012 ($ mil)

Enbrel (Amgen) and Humira (AbbVie) Rheumatoid Arthritis 17,850 Rebif (Merck Serono) Multiple Sclerosis 2,400 Erbitux (Bristol Myers and Eli Lilly) Colon cancer 1,800 Avonex (Biogen) Multiple Sclerosis 1,570 Gonal f (Merck Serono) Induction of ovulation 1,000 Remicade (Janssen Biotech) Rheumatoid Arthritis 970 Sub-Total 25,590

ISRAELI SCIENTIST ABROAD

Joseph Schlessinger - Sutent Kidney cancer 1,236

Aya Jakabovits - XGEVA/Prolia Osteoporosis in Postmenopausal Women 1,220

Aya Jakabovits - Vectibix Cancer of the Large Bowel 359 TOTAL 28,405

2012 Total Global Biopharmaceuticals Market 120,000 ISRAEL INSIDE Contribution (%) 24%

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Personalized Medicine – What is it?

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Sequencing Unit Building on the Weizmann Crown Human Genome Center, the unit will provide High Throughput DNA/RNA sequencing and affiliated bioinformatics to analyse genomic variations, transcriptomes, non-coding RNAs, and editomes.

The Israel National Center for Personalized Medicine Infrastructure

Proteomics Unit Arising from the Weizmann Advanced Mass Spectrometry Lab, the unit will provide quantitative proteomics analyses to study differential expression and post-translational modifications of proteins.

Bioinformatics Unit Build on the Bioinformatics and Biological Computing Group at Weizmann, the unit will use advanced tools to identify promising gene targets, key proteins and critical pathways.

Small Molecules Screening Unit Incorporating the Weizmann Structural Proteomics Unit for protein production and structure determination capacities, the unit will screen small molecule and siRNA libraries for desired biological effects.

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Yeda Research & Development Co. Ltd. Joint Development Process (e.g. Pharmaceutical)

Marketing of a New Drug

FDA Approvals

Clinical Studies

Pre Clinical Research

Basic Research

Innovation

Yeda’s Contribution

Building a Novel Eco System for collaborations

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Yeda Research & Development Co. Ltd. Bridging Research & Development

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

2003 2004 2005 2002 2006 2007 2008 2009 2010 2011 2012 4%

12%

20%

28%

36%

Glo

ba

l M

ark

et

Sh

are

(%

)

44%

52%

58%

66%

Sa

les ($

M)

0

400

800

1200

1600

2000

2400

2800

3300

4000

Yeda Research & Development Co. Ltd.

Source: Annual Companies reports for- Copaxone, Rebif & Avonex

37%

25%

Combining Benevolence & Business

Allow society to benefit from discoveries made at the Weizmann Institute of Science.

Effectively commercialize technologies developed at Weizmann to create additional income for the Institute.

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

* Source: AUTM Licensing Survey 2010

Licensing Income Survey 2010 top 10 Universities *

Institution Licensing Income ($M)

1 City of Hope National Medical Center. & Beckman Research

202

2 Northwestern Univ. 179

3 NYU 178

4 Columbia Univ. 147

5 Sloan Kettering Inst. For Cancer Res. 139

6 Univ. California System 104

7 Wake Forest Univ. 85

8 Univ. of Minnesota 83

9 The General Hospital dba Massachusetts General Hos.

77

10 Univ. of Washington 69

Yeda Research & Development Co. Ltd. Licensing Income

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

403

325

164 144 141

95 90 87 77 77 63 62 61 61 57 57

0

50

100

150

200

250

300

350

400

450

Source: BDI

Israeli Patents in the USA (Accumulated for the Years 2006-2010)

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Yeda Research & Development Co. Ltd. Technologies Portfolio

Biotehnology, 57%

Physics, 7%

Medical devices, 7%

Mathematics, 7%

Chemistry, 11%

Agriculture, 5%

Environmental, 5%

Bioinformatics, 1%

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Yeda Research & Development Co. Ltd. Favorable Environmental Conditions

Legal structure similar to Bayh-Dole act

IP owned by the Institution

Sharing royalty with the inventors

Government support programs

Incubators

Direct tech transfer support programs

Developed investors community, Entrepreneurs

However, a funding gap for series A round

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Yeda Research & Development Co. Ltd. Favorable Internal Conditions

Scientists’ focus on excellence in Basic Science.

A pro-active tech transfer operation: Looking inward for technologies, outward for licensees.

Tech Transfer officers with combined background in both Science & Business.

Resources & willingness to further assess and develop technologies prior to licensing.

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Yeda Research & Development Co. Ltd. A World Leader in Technology Transfer

Dozens of “Weizmann-Inside” products on the market.

Total annual royalty-generating sales in 2012: Over $17 Billion.

Over 70 new companies were established around Yeda’s technologies.

Yeda owns the largest portfolio of patents in Israel: 550 live patent families, with more than 1,700 patent families filed since 1971.

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Yeda / Weizmann Success Stories Anatomies of Success

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Yeda / Weizmann Success Stories Selected Success Stories

ErbituxTM | ImClone

QX Capsule | QuantomiXTM

Yeda / Weizmann Success Stories

Copaxone® | Teva

Rebif

® | Merck Serono

Encryption Algorithm | NDS

GeneCardsTM | XenneX

NanoLubTM | Nanomaterials

Dunaliella | Nikken Sohonsha

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Personalized Technology Transfer!

The Right Agreement for each Technology

Think and Act Globally

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Some Issues

Invention disclosures are made locally but will be examined on a country by country basis.

How do we deal with the reporting requirements under the Bayah Dole Act?

What are the requirements of the local R&D encouragement laws?

Patent Law

USA finally moving to first to file

Where to enforce?

Joint owners

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Cont’d.

Laws relating to import and export:

Limitation on export and import

Antitrust law (grant back, royalty term)

EU Technology Transfer Block Exemption

Antitrust Guidelines for the Licensing of Intellectual Property

Laws relating to Pre-Clinical, Clinical trails and other regulatory agencies.

Tax issues such as withholding tax.

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Non-exclusive license is suitable in cases where the technology is relatively matured and could be used as a research tool or becomes an industry standard.

Points to consider:

Choice of law and forum

Improvements

Most Favored Nation Clause

It gets really complicated with non-exclusive deals

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

Israeli Model

Sublicensing

Assignment

M&A

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. Yeda R&D Co. Ltd, Nanjing IP Seminar Adv. Galit Yosha March 22-23, 2012

38

(Bismark)

Murphy’s law:

Technology Transfer from the Weizmann Institute of Science

Yeda Research & Development Co. Ltd. w w w . Y e d a R n D . c o m

www. YedaRnD. c o m T h a n k y o u